Intradermal Microneedle Patch
Pain Management
Pre-clinicalActive
Key Facts
About Isosceles Pharmaceuticals
Isosceles Pharmaceuticals is a private, preclinical-stage biotech founded in 2019, targeting the massive and growing acute pain market with intravenous and intradermal formulations of synthetic cannabidiol. The company's strategy centers on bypassing first-pass metabolism via parenteral delivery to achieve fast onset and high bioavailability, positioning its candidates as potential alternatives to addictive opioids. Led by a team with extensive experience in pain product development, Isosceles is operating in a high-need area driven by the opioid epidemic and increasing surgical volumes, though it faces significant development and regulatory risks common to early-stage drug developers.
View full company profileTherapeutic Areas
Other Pain Management Drugs
| Drug | Company | Phase |
|---|---|---|
| Authorized Generic of Nucynta® ER (tapentadol) | hikma | Launched |
| Authorized Generic of Nucynta® (tapentadol) | hikma | Launched |
| Non-addictive poppy-derived analgesic | Emerzene | Pre-clinical |
| LymphaTouch Device | Lymphatouch | Commercial |
| Generic Oxycodone ER (Oxycontin) | Natco Pharma | Launched |
| Generic Tapentadol ER | Hikma Pharmaceuticals | Approved |
| Generic Tapentadol | Hikma Pharmaceuticals | Approved |